病毒及疫苗研究技术交流会

作者:   2014-08-19
字体大小:
  • 会议时间: 2014-09-10至 2014-09-10
  • 会议地点: 北京
  • 电话:18911867706
  • 传真:
  • 联系人:林先生
  • Email: linsen@applitechpharma.com
  • 联系地址:
  • 会议网址:

Virus and Vaccine Research Technical Exchange Seminar

快速定量病毒及其在病毒研究和疫苗生产中的应用 

时间:2014年9月10日,星期三, 8:30-13:00

地点:北京希尔顿酒店三层里程厅 

研讨会主题: 

疾病预防和控制一直是全球范围内备受关注,近年来几次大规模流行性疾病再次给我们敲响警钟。中国作为人口大国,公共卫生和疾病防预一直以来都是一个重大课题和挑战。病毒研究和疫苗研发生产是疾病防预的基本,目前中国病毒研究课题已达上万个,在用疫苗近百种,中国已然成为公共卫生和疾病预防的主战场。 

公共卫生和疾病预防依赖于科学技术的进步,随着科学的发展,人们对有病毒导致疾病有了深入的了解,在对病毒研究的基础上,开发了用于预防病毒感染的预防性疫苗和对抗病毒的治疗性药物。然而,无论是研究人员的对病毒开展的基础研究,还是在开发治疗和预防病毒性药物过程中,如何评判当前研究对象是一个亟需解决的课题。在目前的应用过程中,研究和生产人员需要花费大量的时间才能给出相应的结果,这样既严重影响研究和生产的效率,同时也不利于质量的管控;并且由于人为的干预,往往得的结论存在较大的分歧。因此,一个快速、有效、通用的方法势必为研究和生产提供稳定可靠的结果,缩短研究生产周期,调高效率,便于质量管理。 

美国大使馆一直致力于新技术在全球的推广活动。本次活动很荣幸能够邀请Virocyt公司,在亚洲推广其全新的技术,为人类的疾病研究和预防做出贡献。Virocyt公司一直致力于病毒和疫苗研究领域,其全新的技术已经在全球范围内受到广泛的关注,如:Merck,Sanofi Pasteur, Novartis,Boehringer Ingelheim等都已经在其研究和疫苗研发生产中应用这一技术。 

Disease control and prevention has been a worldwide attention. In recent years, several large-scale epidemic disease alarms us again. China as a big country, public health and disease prevention has always been her major issues and challenges. Virus research and vaccine R&D and production is the basic of disease prevention, virus research subject at present in China has reached tens of thousands, and vaccine in using nearly hundred kinds, China has become the main public health and disease prevention. Public health and disease prevention depends on the progress of science and technology. As the science developing, people have an insight into
the virus causing disease. Base on the research on virus, preventive vaccine is developed for preventing infection and antiviral therapeutic drugs. However, neither the researchers for the virus to carry out basic research, nor in the process of development of the treatment and prevention of viral drugs, how to judge the current research subject is an urgent topic to be solved. In the process of application, the researcher and operator will take a lot of time to give the corresponding results, so it  seriously affects the efficiency of research
and production,  and the control of quality at the same time; And because the human intervention,  the conclusion is a big differences. Therefore, a rapid, effective and general method is bound to provide research
and production is stable and reliable results, shorten the production cycle, high efficiency, easy to quality management.

The US embassy is committed to the promotion of new technology in the world.It is a great pleasure to invite Virocyt company to promote its new technology in Asia,contributing to human disease research and prevention. Virocyt company has been committed to the virus and vaccine research field, the new technology has been
widely attention worldwide, such as: Merck, Sanofi Pasteur and Novartis,Boehringer Ingelheim etc. These company have used Virocyt technology in the research and development of vaccine. 

会议的主要演讲人和演讲题目:

USA embassy: To bridge gap the technology and the application Sarah Kemp,The Minister Counselor for Commercial Affairs of the Embassy of the United States of America Introduction of the new technology and case study of VC system in virus research and vaccine manufacturer Craig Hoechstetter, VP,Virocyt, Craig has years of experience of virus research and virus quantification.  He works closely with organizations such as Sanofi Pasteur, Merck, FDA, and NIH to help them to improve their virus quantification processes. 

Flow Cytometry differentiate Virus Counts from Egg and Cell Culture

Dr. Ewan Plant, USA FDA,Dr.Ewan Plant is working at the U.S Food and Drug Administration.  Since 2009
his research and regulatory activities for the Office of Vaccine Research and Review have focused on influenza vaccines.  He received his Ph.D. in biochemistry from the University of Otago in New Zealand, and has ublished
research related to virus replication and ribosome fidelity. 

New technology for qualification of virus in research and vaccine production 

Zhidong Wei. Lanzhou Institute of Biological Products (LIBP). As one of the major subsidiary biological
hi-tech enterprises under China National Biotech Cooperate (CNBP), Lanzhou Institute of Biological Products (LIBP) is engaged in the R&D, training, manufacture and marketing of biological products. The institute is an important scientific research organization in China in the fields of Medical microbiology, Immunology, and
Molecule-biology. It has been honorablely selected as one of the industrialized basements for National 863 Program under the Ministry of Science &Technology; hi-tech industrialized model unit of National Development and Reform Committee and as state certified technical center of enterprises.Moreover, the institute is authorized to  confer the Master’s degree and appointed as post-doctor working station. It is supplier of rehabilitation-drug for so-called “Tomorrow Plan” project by the Ministry of Civil Administration as well

编辑: meeting201   

声明:

1.丁香会议频道仅负责发布会议信息,如需参会、获取邀请函或会议日程,请与主办单位联系

2.部分会议信息来自互联网,如您发现信息有误,请联系meeting@dxy.cn纠错

3.如您发现信息不全,可点击Google搜索更多

4.更多服务信息请点击这里